When tested in a mouse model of breast cancer, the doxorubicin-loaded nanoparticles caused fewer side effects than free doxorubicin.

The ability to make patient-specific products quickly fits with the needs of smaller, resource-limited developers.

For some trees, wasted bark is a potential treasure-trove of biopharmaceuticals—from anti-inflammatories to cancer-fighting ...

FDA Commissioner Martin Makary, MD, shared his vision for a “New FDA” with biopharma leaders attending BIO in Boston.

Barcelona’s blood and tissue bank says it has developed a new system for the large-scale production of mesenchymal stromal ...

Bionova will also use Cytiva’s Fast Trak process development services to help advance their entry into genomic medicines.

QurAlis’ new headquarters offers enhanced lab and discovery resources and a 5,000-sq-ft conferencing space for meeting and ...

The AI unicorn's Perturb-seq atlas is publicly available and detects dose-dependent genetic effects to enhance predictive ...

In addition to being faster and less invasive than a traditional tissue biopsy, the blood test is also potentially more ...

By designing proteins de novo scientists can more efficiently create novel therapeutics tailored for specific biological ...

Chrysalis partners with life science clients, from early-stage biofirms to pharmaceutical firms, CROs, and other life science ...

PepGen leverages a graph-based approach to improve the detection of hidden protein variants in a computationally efficient ...